This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock
Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.